Dr. Ferenc Tracik has been appointed chief medical officer of Neumirna Therapeutics, a Copenhagen-based biotechnology company developing microRNA-targeted therapies for neurological disorders, according to an announcement by recruiting firm Coulter Partners in May 2026. Tracik, a neurologist with more than two decades of experience in neurological and rare disease drug development, will oversee medical and clinical strategy, patient safety, regulatory interactions, and external medical affairs. He will work alongside the company's chief development officer to advance the lead program NMT.001 into clinical trials in early 2027 and guide a preclinical program in Parkinson's disease.
Ellen Donnelly, CEO of Neumirna, framed the appointment as marking an inflection point for the company, moving from scientific validation to patient impact. Donnelly said Tracik possessed both the technical depth in central nervous system development and the commercial launch experience necessary for the next growth phase. Nanna Soni, a client partner at Coulter Partners, emphasized that Tracik was uniquely qualified to bridge Neumirna's pioneering research with patient applications, noting that the search firm's deep expertise in antisense oligonucleotide and RNA landscapes enabled a precise identification process.
Tracik brings substantial translational experience from previous roles in commercial drug development. Most recently, he served as chief medical officer at NeuroSense Therapeutics, where he led global Phase 2 programs in amyotrophic lateral sclerosis and Alzheimer's disease, including a successful FDA investigational new drug submission. Before that, he held the position of vice president for Europe, Canada, and partner markets at Biogen, where he led the European medical launch of an antisense oligonucleotide for spinal muscular atrophy. During his Biogen tenure, he established a multinational SMA registry and supported one of the largest global expanded access programs for the disease. His career also encompasses leadership roles at Novartis and Teva.
Neumirna was founded in 2020 by Dr. Henrik Klitgaard, Professor Sakari Kauppinen, and Lars Hellerung Christiansen with the mission of developing disease-modifying RNA therapies for challenging neurological conditions. The company raised 20 million euros in Series A funding in January 2025, co-led by Angelini Ventures and Invivo Partners with participation from Innovestor. The capital is supporting clinical development of NMT.001, an antisense oligonucleotide targeting drug-resistant epilepsy, which represents a substantial unmet medical need. Neumirna's platform also addresses Parkinson's disease through preclinical programs.
Tracik's appointment reflects a broader strategy by emerging RNA therapeutics companies to recruit senior medical leaders with regulatory and commercial track records as their programs mature toward the clinic. His background in successfully implementing antisense oligonucleotide launches at Biogen and managing clinical programs addressing severe neurodegenerative diseases suggests Neumirna is preparing to scale operations beyond research into the regulatory and commercial phases of development. The timing of the hire, occurring months after the company's Series A funding close, indicates management is building the clinical infrastructure necessary to transition NMT.001 and its pipeline candidates from preclinical validation to human studies.
